Replies to post #209619 on Biotech Values

[DewDiligence]

Is there a probability that FMI will update their 2017 guidance in regards to recently receiving medicare payment for NSCLC? Does anyone think this development is substantial enough to move the needle?

The question is what internal assumptions are baked into FMI's existing guidance. If they anticipated getting Medicare reimbursement for NSCLC tests in early 2017, then this news wouldn't in itself cause an upward revision in guidance.

p.s. I don't follow FMI as closely as I did two years ago.